VKTX – VektorTx, Inc.

Latest News & Stock Analysis

VektorTx, Inc., (VKTX) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of common cancers. VektorTx employs a unique approach by developing tumor-selective, next-generation oncolytic viruses designed to maximize efficacy and minimize systemic toxicity. Investors interested in biotechnology stocks and cancer treatment advancements will find VKTX an interesting investment to analyze. Stay updated with the latest news on VKTX stock, market trends, and in-depth analysis to make informed investment decisions.

Viking Therapeutics Surges on Pfizer Buyout Speculation
VKTX

Viking Therapeutics Surges on Pfizer Buyout Speculation

by | 14/04/2025 04:00 AM | VKTX

🤔 Speculation arises that Pfizer might acquire Viking Therapeutics following the halt of Pfizer's own weight-loss drug development.

📈 Viking Therapeutics' stock price saw an uptick, potentially fueled by these buyout rumors in the market.

💰 The video notes Viking's significant price drop from previous highs (around $100 down to $22) and mentions a potential acquisition price around $2.5 billion.

Read more!